Ms
Roxna
Kapadia

Patent Director

London Office

Life sciences

Telephone. +44 20 7776 5100
Email. [email protected]
Vcard
Linkedin

Experience

Roxna is a UK and European qualified patent attorney with in-depth knowledge and experience with viral cancer therapeutics, antibodies, stem cells, immunotherapy, genetics and food science. Roxna has in-house patent experience working at the small biotechnology company Oncolytics Biotech Inc. and at the multinational company General Electric Healthcare and Merck Sharp & Dohme.

Roxna has experience working before the EPO, UKIPO and WIPO, including drafting and filing applications, prosecution and EPO oppositions and appeals. Roxna also has extensive experience with IP due diligence, validity opinions and FTO analysis. Having worked both in house and in private practice, Roxna is well placed to provide business focused strategic intellectual property advice to her clients.

Roxna is a named inventor on a patent for a method of purifying viruses using gel permeation chromatography. Roxna developed and ran industry-focused intellectual property courses in London UK. In particular Roxna has taught Freedom to Operate courses for the Life Sciences and Pharmaceutical Industry.

Having grown up in Canada and worked in Switzerland, Roxna is fluent in English and French.

Specialisms

Industries

Services

Qualifications

Patent Attorney

Chartered (UK)
Europe

BSC

Microbiology and Immunology

MSC

Immunology

MSC

Management of Intellectual Property

Related News

Event - 8th-9th February 2023

5th Annual Microbiome & Probiotic Conference 2023

The 5th Annual MarketsandMarkets Next Gen Microbiome and Probiotics Conference will take place in San Diego on the 8th-9th of February. This conference will enable you to learn about microbial …

Event details
Event - 17th January 2023

CIPA Webinar: Enhancing Diversity in the Patent Profession How Can I Help

CIPA hosted a webinar to discuss ‘Enhancing diversity in the patent profession.’ Date Tuesday 17 January, 2023 Time 12.30pm – 1.30pm (GMT) Equity, diversity and inclusion has been in the …

Event details

LiDAR: A Significant Support Technology at CES

When visiting CES’ one thing that struck me was the number of companies demonstrating LiDAR technology. LiDAR has been around since the 1960s and was originally developed for aerospace use, …

Read article

Healthcare and Climate Change

Can we find a balance between intellectual property rights and public health needs when tackling the climate crisis? “The world faces a critical juncture. A health-centred, aligned response to the …

Read article

Navigating the CRISPR IP confusion

It is just over 10 years since the Science publication of Jinek et al. showed for the first time that DNA cleavage could be achieved in vitro with a Cas9 …

Read article

CRISPR Edited T cells win the TvT Battle

T-cells which have been modified using CRISPR base editing technology have been successfully used to treat T-cell acute lymphoblastic leukaemia for the first time {1}. A 13 year old patient …

Read article

Dot Inc, the accessible future and more: health tech highlights coming to CES 2023

The countdown is on for CES 2023. Taking place in Las Vegas in the first week of January each year, CES sets the global stage for innovation in the tech …

Read article

Can AI replace patent attorneys?

OpenAI recently released a dialogue-based AI chatbot called ChatGPT, which is free for anyone to try out. You can try it here (https://chat.openai.com/chat). It’s been shown that it can set, …

Read article
See all updates

Let's talk

If you would like to discuss how HGF could help you, contact one of our IP specialists.

Contact us